The FDA has granted accelerated approval to amivantamab and hyaluronidase for advanced HNSCC based on the OrigAMI-4 trial.

Andrea Necchi, MD, discusses response-adapted treatment, higher complete response rates, and the potential to reduce the need ...

The planned study will evaluate the investigational PET imaging agent in approximately 280 patients with indeterminate brain ...

Personalized ctDNA monitoring guides adjuvant therapy and flags head and neck cancer relapse months early, showing high ...

In OptimUM-01, first-line darovasertib plus crizotinib produced a 34.1% ORR and 21.1-month median OS in metastatic uveal ...

At ESMO 2026, experts forecast how RAS inhibitors, new prostate cancer therapies, and IO combinations may reshape pancreatic, ...

Morana Vojnic, MD, MBA, explains how FET-PET imaging's FDA approval is enabling neuro-oncologists to identify ...

Perioperative enfortumab vedotin plus pembrolizumab had a cost-effectiveness ratio of $72,460 per QALY vs radical cystectomy ...

FDA final guidance sets a risk-based potency assurance roadmap for cell and gene therapies, spanning development, ...

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, discusses how Breakthrough Therapy Designation and ...

Targeted Onc connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Jacob Sands, MD, discusses the top findings from the phase 3 DeLLphi-305 study evaluating tarlatamab and durvalumab as ...